Serial #97251461
LIVE

Serial Number

97251461

Owner

Performance Cell Manufacturing, Inc.

Attorney

Paul J. Kennedy

First Use Date

Feb 14, 2022

Filing Date

Feb 3, 2022

Add to watchlist:

No watchlists yet
View on USPTO

Serial #97251461 Trademark

Serial Number: 97251461 • Registration: 7375159

Serial #97251461 is a trademark filed by Performance Cell Manufacturing, Inc. on February 3, 2022. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Performance Cell Manufacturing, Inc. (2 trademarks)

12860 Danielson Court, Suite B
Poway, CA 92064

Entity Type: 03

Trademark Details

Filing Date

February 3, 2022

Registration Date

April 30, 2024

First Use Anywhere

February 14, 2022

First Use in Commerce

February 14, 2022

Published for Opposition

July 4, 2023

Goods & Services

Manufacturing services for others in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals, namely, custom manufacture of pharmaceuticals, chemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing services for others in the fields of mammalian cell banks, plasmids, purified mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians, namely, custom manufacture of pharmaceuticals, chemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing process consulting; Production in the nature of custom manufacture of cell lines for others using lentivirus technology; Production in the nature of custom manufacture of a recombinant or manipulated lentivirus; Production in the nature of custom manufacture of mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians

Providing regulatory compliance and regulatory compliance consultation and advisory services with respect to relevant state and federal law for organizations in the pharmaceutical, biotech, life science, and other government-regulated industries

Research and development in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, research and development in the fields of assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services, namely, research and development in the fields of assaying, and purifying mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; CDMO (Contract Development and Manufacturing Organization) services, namely, pharmaceutical drug development services; material testing; product quality testing; scientific laboratory services; scientific research

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 30, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 30, 2024 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 29, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 28, 2024 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Mar 6, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 6, 2024 AITU
USE AMENDMENT FILED
Feb 14, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Feb 14, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 29, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 4, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 4, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 14, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 1, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 24, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 24, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 28, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 28, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 28, 2022 CNRT
ASSIGNED TO EXAMINER
Nov 16, 2022 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 9, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 8, 2022 NWOS
NEW APPLICATION ENTERED
Feb 7, 2022 NWAP